Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant ...

RASolute 304 is anticipated to enroll approximately 500 patients with PDAC harboring oncogenic RAS mutations who have undergone resection and completed perioperative chemotherapy. The trial will ...
Benzinga.com

Unusual Options Activity as of Dec 19th

10 Consumer Discretionary Stocks Whale Activity In Today's Session 10 Information Technology Stocks Whale Activity In Today's Session Unusual options activity (unusual options) occurs when trading ...
Scientific Research Publishing

Applying Deep Learning Techniques for Automated Analysis and Interpretation of Financial Statements ()

Multimodal Learning, Deep Learning, Financial Statement Analysis, LSTM, FinBERT, Financial Text Mining, Automated Interpretation, Financial Analytics Share and Cite: Wandwi, G. and Mbekomize, C. (2025 ...

Academy Sports + Outdoors Reports Third Quarter Fiscal 2025 Results; Updates Guidance

KATY, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Academy Sports and Outdoors, Inc. (Nasdaq: ASO) ("Academy" or the "Company") today announced its financial results for the third quarter ended November 1 ...